ArticleJournal of proteome research2026
Evaluating and Optimizing Mass Spectrometry Proteomics Data to Deconvolve Cell-Type-Specific Protein Expression in Tumors.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatial Proteomics as a Potential Decision-Support Layer for Early Melanoma: A Narrative Review.International journal of dermatology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Understanding intratumoral heterogeneity is essential for elucidating tumor biology. Compared to RNA expression, omics-level characterization of cell-type-specific protein expression remains a technical challenge. Bulk mass spectrometry (MS) provides abundant proteomics resources to infer cell-type specificity via data deconvolution; however, it is unclear which proteomic quantification formats are optimal, as they differ from the data types for which most deconvolution methods were designed. Here, leveraging recently generated large-cohort proteogenomics data, we systematically evaluated different MS proteomics quantification formats and preprocessing strategies to resolve cell-type-specific protein expression. Our results indicate that while label-free spectral counts can be used directly, TMT MS1 intensities and MS2 ratios are less suitable and require appropriate data transformation. We demonstrate that a 'min-score' transformation significantly improves MS1 intensity-based deconvolution, providing useful insights for subtyping pancreatic cancer. Moreover, we identified the coefficient of variation (CV) as a robust statistical indicator of deconvolution suitability. Finally, we developed "ProTransDeconv", an R package integrating data transformation, deconvolution, and quality checks for major MS proteomics data formats. This work provides practical guidance for deconvolving bulk proteomics to study cell-type-specific protein-level dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.